notice. KGOG 2025 캠페인 희망 더하기, 부인암 연구기금 마련 걷기대회. more

Korean Gynecologic Oncology Group. The mission of our society is to protect women from fatal threats by conquering gynecologic cancer.

In the original cohort (O) of KGOG 3046 study (NCT03899610) on newly diagnosed advanced-stage epithelial ovarian cancer (aEOC), patients receiving neoadjuvant chemotherapy (NAC) with durvalumab [D] and multiple low dose of tremelimumab [T] exhibited promising long-term survival outcomes. After completing enrollment of the original cohort, an expansion cohort (E) was initiated with a regimen of ...

2021年12月6日 · INTRODUCTION. Worldwide, there is an estimated 313,959 patients with ovarian cancer, and 207,252 deaths related to the disease are recorded annually [].Most patients receive platinum-based chemotherapy, but despite aggressive treatment, about 80% of patients at an advanced stage experience recurrence that is ultimately fatal.

2023年12月15日 · Choosing an optimal concomitant drug for combination with poly-ADP ribose polymerase (PARP) inhibitor based on patient-specific biomarker status may help increase to improve treatment efficacy in patients with ovarian cancer. However, the efficacy and safety of different PARP inhibitor-based combina …

2024年10月9日 · The Korean Gynecologic Oncology Group (KGOG) was established in 2002 and is the only organization in Korea conducting multi-center clinical trials for gynecologic cancers. Since its re-establishment as a non-profit organization in 2021, KGOG has grown significantly, now including 207 gynecologic onc …

Background: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 antibody) to chemotherapy in treating this cancer can increase progression ...

Bureau of the Korean Gynecologic Oncology Group 2-ho, 2nd Floor, 32, Nambusunhwan-ro 333-gil, Seocho-gu, Seoul 06725, Korea

2.3. Interaction with Other International Research Organizations. Since its establishment, the KGOG has collaborated with prominent international institutions leading multi-center research, such as the GOG Legacy and NRG in the United States, European Network for Gynaecological Oncological Trial group (ENGOT) in Europe, and the Gynecologic Cancer InterGroup (GCIG).

We hypothesized that adding durvalumab and tremelimumab to neoadjuvant chemotherapy (NACT) in advanced-stage epithelial ovarian cancer (aEOC) would increase progression-free survival (PFS) with minimal adverse effects. Here, we report the final primary endpoint in the original cohort of the KGOG 3046 study on NACT with dual immune checkpoint blockade (durvalumab and tremelimumab) in newly ...